EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion

Cesare Gridelli, Marcello Tiseo iD, Diego Luigi Cortinovis iD, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili iD, Filippo de Marinis

Current Oncology · 2023

DOI: 10.3390/curroncol30110729 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2023. Verfasst von Cesare Gridelli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, "S.G. Moscati" Hospital, 83100 Avellino, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana di Oncologia Toracica (AIOT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ALK tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and largely improved the survival outcomes of patients with NSCLC harboring ALK rearrangements. Different ALK TKI compounds have demonstrated antitumor activity in these patients and are available in clinical practice. However, clinical expertise across countries varies according to local regulatory approval of different drugs, identifying multiple treatment scenarios to comply with international guidelines and clinical practice.

Methods

A virtual webinar was held on July 2023 to discuss the state of the art and future perspectives in the treatment of ALK rearrangement in advanced NSCLC in Italy. The faculty hosting the webinar was composed of eight medical oncologists from different regions of Italy with clinical expertise in treating patients with lung cancer. Live-shared notes were used to produce a report to serve as the basis of a review manuscript on the topic.

Results

Alectinib and brigatinib are the preferred front-line treatment options in Italy, pending approval of the front-line medicine lorlatinib, which would be considered among the choices. Due to a local regulatory limitation of second-line lorlatinib, which is not allowed after front-line brigatinib, alectinib is commonly the preferred front-line choice to follow a sequence of alectinib, followed by lorlatinib, followed by platinum plus pemetrexed chemotherapy. Age and performance status were not considered per se as clinical features influencing treatment choice. However, treatment compliance is deemed a relevant factor in decision making with regard to the number of pills to be administered. In general, given the availability of alternative choices, the spectrum of patients’ comorbidities and polypharmacotherapy interactions should be taken into account in treatment selection according to the toxicity profile of each compound. In addition, several issues were debated with regard to improving treatment outcomes, including testing, brain metastases, and management of an oligoprogressive disease.

Conclusions

The treatment scenario of ALK-positive disease is dynamically evolving. Furthermore, not all FDA- and EMA-approved compounds are approved in Italy with the same indications. This influences therapeutic opportunities and increases the need for greater clinical expertise to help and guide treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansAnaplastic Lymphoma KinaseProtein-Tyrosine KinasesTyrosine Kinase InhibitorsProtein Kinase InhibitorsLactams, MacrocyclicAminopyridinesLactamsPyrazolesOrganophosphorus CompoundsPyrimidines

Stichwörter der Autor:innen

ALKalectinibbrigatiniblorlatiniblung cancer

Substanzen

Anaplastic Lymphoma KinaseProtein-Tyrosine KinasesTyrosine Kinase InhibitorsProtein Kinase InhibitorsLactams, MacrocycliclorlatinibAminopyridinesLactamsPyrazolesbrigatinib

Autor:innen und Institutionen

  • Division of Medical Oncology, "S.G. Moscati" Hospital, 83100 Avellino, Italy.
  • Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
  • Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
  • SC Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
  • Department of Oncology, San Camillo-Forlanini Hospital, 00152 Rome, Italy.
  • Medical Oncology Unit, AOU Renato Dulbecco, 88100 Catanzaro, Italy.

ORCID-Profile: Marcello Tiseo, Diego Luigi Cortinovis, Ilaria Attili

Förderung

  • Associazione Italiana di Oncologia Toracica (AIOT)

Zitieren

APA

Gridelli, C., Tiseo, M., Cortinovis, D. L., Migliorino, M. R., Barbieri, V., Bironzo, P., Bearz, A., Attili, I., & de Marinis, F. (2023). Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion. Current Oncology. https://doi.org/10.3390/curroncol30110729

Vancouver

Gridelli C, Tiseo M, Cortinovis DL, Migliorino MR, Barbieri V, Bironzo P, et al. Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion. Current Oncology. 2023. doi:10.3390/curroncol30110729

BibTeX
@article{Gridelli2023,
  author = {Gridelli, Cesare and Tiseo, Marcello and Cortinovis, Diego Luigi and Migliorino, Maria Rita and Barbieri, Vito and Bironzo, Paolo and Bearz, Alessandra and Attili, Ilaria and de Marinis, Filippo},
  title = {Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30110729}
}
Kostenlos starten →